Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Buchang Pharmaceuticals Co (SHSE:603858) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shandong Buchang Pharmaceuticals Co EBITDA Margin % Related Terms
Shandong Buchang Pharmaceuticals Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Buchang Pharmaceuticals Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Buchang Pharmaceuticals Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Buchang Pharmaceuticals Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Buchang Pharmaceuticals Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Shandong Buchang Pharmaceuticals Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Buchang Pharmaceuticals Co (SHSE:603858) has a EBITDA Margin % of 15.95% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Buchang Pharmaceuticals Co and its competitors. This is near median its historical median of 15.60. According to the industry distribution chart, Shandong Buchang Pharmaceuticals Co ranks #636 out of 961 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Shandong Buchang Pharmaceuticals Co's EBITDA Margin % too high?
Shandong Buchang Pharmaceuticals Co's current EBITDA Margin % of 15.95% is near median its 10-year median of 15.60. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Shandong Buchang Pharmaceuticals Co's value of 15.95% is 28.7% above this industry median. Based on the distribution chart, Shandong Buchang Pharmaceuticals Co ranks #636 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shandong Buchang Pharmaceuticals Co has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shandong Buchang Pharmaceuticals Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shandong Buchang Pharmaceuticals Co ranks #636 out of 961 companies for EBITDA Margin %. This places Shandong Buchang Pharmaceuticals Co in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Shandong Buchang Pharmaceuticals Co's value of 15.95% is 28.7% above this benchmark. While the company's 10-year median is 15.60 vs. the industry median of 12.39, Shandong Buchang Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Buchang Pharmaceuticals Co's current EBITDA Margin % of 15.95% is 28.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shandong Buchang Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Buchang Pharmaceuticals Co's current EBITDA Margin % is 15.95%, which is near median its own 10-year median of 15.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Buchang Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co (SHSE:603858) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.94, compared to a current price of ¥15.66 — trading 1.8% below its estimated fair value. The current EBITDA Margin % is 15.95%, which is near median its 10-year median of 15.60 and 28.7% above the Drug Manufacturers industry median of 12.39. Shandong Buchang Pharmaceuticals Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shandong Buchang Pharmaceuticals Co (SHSE:603858), the current EBITDA Margin % is 15.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Buchang Pharmaceuticals Co (SHSE:603858) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥15.66 is trading 1.8% below its estimated GF Value™ of ¥15.94.
GuruFocus considers Shandong Buchang Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:603858:
EBITDA Margin %: 15.95% (near median its 10-year median of 15.60)
GF Value™: ¥15.94 vs. price of ¥15.66 (1.8% below fair value)
Industry Position: 28.7% above the Drug Manufacturers median (#636 of 961)
No single metric tells the full story. See the SHSE:603858 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603858 has been successfully added to your 
